Navigation Links
Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update
Date:3/16/2009

$49.1 million) for the year ended December 31, 2008, compared with a net loss of $32.8 million ($1.08 diluted loss per share on a loss applicable to common shares of $33.3 million) for the year ended December 31, 2007.

Total operating expenses for the quarter ended December 31, 2008, were $13.4 million compared with $10.4 million for the quarter ended December 31, 2007. Total operating expenses were $49.2 million for the year ended December 31, 2008, compared with $35.4 million for the year ended December 31, 2007.

Research and development (R&D) expenses were $10.2 million for the quarter ended December 31, 2008, compared with $7.0 million for the quarter ended December 31, 2007. R&D expenses were $34.7 million for the year ended December 31, 2008, compared with $23.4 million for the year ended December 31, 2007.

General and administrative (G&A) expenses were $3.2 million for the quarter ended December 31, 2008, compared with $3.5 million for the quarter ended December 31, 2007. G&A expenses were $14.4 million for the year ended December 31, 2008, compared with $12.1 million for the year ended December 31, 2007.

Cash and investment securities as of December 31, 2008, were $72.8 million, compared with $92.6 million at December 31, 2007. Taking into account the $17.9 million minimum unrestricted cash that the Company is required to maintain under its loan facility with GE Healthcare Financial Services and Silicon Valley Bank and the Company's projected operating results, the Company believes that its existing cash and investment securities will provide adequate resources to fund the Company's operations at least into the first quarter of 2010. However, given the uncertainties of outcomes of the Company's ongoing clinical trials, there is no assurance that the Company can achieve its projected operating results. Accordingly, the report of the Company's independent registered public
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
6. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
7. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
9. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
10. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
11. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 , ... Dr. Ra from Biostar , Published in ,Stem ... increase of lifespan through multiple IV administration of Adipose-derived ... and life expectancy found , Commercialization within 5 ... determined the possibility that adult mesenchymal stem cells (MSCs) ...
(Date:8/27/2015)... Va. , Aug. 27, 2015  The ... the Food and Drug Administration,s (FDA,s) draft guidance ... reference products and biosimilars, to bear a nonproprietary ... AMCP has been seeking a decision from the ... 18 diverse health care stakeholders urging the agency ...
(Date:8/27/2015)... , August 27, 2015 According to a ... Hammock, Toilet, Seating, Universal, Standing, Bariatric ), Material (Nylon, Padded, Canvas), ... to 2020", published by MarketsandMarkets, the Medical Lifting Sling Market is ... Million in 2015, at a CAGR of 11.4 % from 2015 ... ma rket data T ables and ...
Breaking Medicine Technology:Korean Researchers Find the Possibility that Adult Mesenchymal Stem Cells (MSCs) May Extend Lifespan 2AMCP Is Disappointed in FDA's Draft Guidance and Proposed Rule Calling for Suffix on Nonproprietary Names of Biological Products 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 3Medical Lifting Sling Market Worth USD 706.0 Million by 2020 4
(Date:8/28/2015)... ... 2015 , ... Saint Petersburg, FL —Pocket Protein™, a protein ... sugar, gluten, lactose or caffeine in a convenient 2 oz. pouch that never ... Choice Awards. , Five consumer packaged goods (CPG) products were selected by the ...
(Date:8/28/2015)... , ... August 28, 2015 , ... ... nationwide. Addictions specialist, Dr. James Strawbridge, gives a new approach on solutions in ... should begin with the employer and employees getting together for meaningful group meetings. ...
(Date:8/28/2015)... , ... August 28, 2015 , ... ... three-year accreditation for its adolescent residential, counseling, day treatment and intensive family based ... meets international standards for quality and its pursuit of excellence. As a nonprofit ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Quatela Center for Plastic Surgery is ... and only nonsurgical product approved by the Food and Drug Administration to eliminate submental ... Dr. William Koenig are among the premier cosmetic surgeons in Rochester to ...
(Date:8/28/2015)... ... 28, 2015 , ... SharkNinja, an innovative leader in the ... actress, Sofia Vergara, and unveil the Ninja® brand’s new coffee machine, the ... a variety of sizes and styles while achieving the perfect brew richness level ...
Breaking Medicine News(10 mins):Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3Health News:West Ridge Academy Awarded CARF Three-Year Accrediation 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 3Health News:Sofia Vergara Partners With SharkNinja® To Launch The Ninja Coffee Bar™ 2Health News:Sofia Vergara Partners With SharkNinja® To Launch The Ninja Coffee Bar™ 3
... PARIS and MARSEILLE, France, January 11 ... signing of a,scientific collaboration agreement in the breast cancer domain. ... Ipsogen,s,MapQuant Dx Grade Genomic, HER2 and HR tests will be ... patients treated at the Institut,Curie. The aim of this collaboration ...
... , CHICAGO, Jan. 11 ... Stimulus Program , making it safe and easy for physicians ... qualify for significant federal incentives. , (Logo: http://www.newscom.com/cgi-bin/prnh/20081013/AQM041LOGO ) ... a guarantee that the Allscripts EHR they select will meet ...
... , , ... MDRX ) announced today that Renaissance Medical Management Company (RMMC) ... Practice Management solution to automate and connect clinical and ... medicine physicians. The new service offering from RMMC builds upon the ...
... ... months and shared his story on ABC,s Good Morning America on January 8, 2010 , ... New York, NY (PRWEB) January 11, 2010 -- ... ago, kicked off 2010 with an appearance on ABC,s Good Morning America last Friday, feeling and ...
... ... simply spelling correctly the Hebrew word Sun ( SheMeSh éÞé) in English Letters as ... ... years of research, Joseph Lanyadoo concludes that language was neither invented by humans ...
... , CHICAGO, Jan. 10 Allscripts-Misys Healthcare ... for the three and six months ended November 30, 2009. ... Highlights: , Total revenue of $169.3 million; non-GAAP ... cents; non-GAAP earnings per share of $0.16 cents Net income ...
Cached Medicine News:Health News:The Institut Curie and Ipsogen Sign a Scientific Collaboration Agreement Relating to the Genomic Grade, a Molecular Diagnostic Tool for Breast Cancer 2Health News:The Institut Curie and Ipsogen Sign a Scientific Collaboration Agreement Relating to the Genomic Grade, a Molecular Diagnostic Tool for Breast Cancer 3Health News:Allscripts Announces Rapid Implementation, 'Meaningful Use' Guarantee, and Financing Programs for Electronic Health Records 2Health News:Allscripts Announces Rapid Implementation, 'Meaningful Use' Guarantee, and Financing Programs for Electronic Health Records 3Health News:Allscripts Announces Rapid Implementation, 'Meaningful Use' Guarantee, and Financing Programs for Electronic Health Records 4Health News:Allscripts Announces Rapid Implementation, 'Meaningful Use' Guarantee, and Financing Programs for Electronic Health Records 5Health News:Allscripts Announces Rapid Implementation, 'Meaningful Use' Guarantee, and Financing Programs for Electronic Health Records 6Health News:Renaissance Medical Management Company Selects Allscripts Electronic Health Record and Practice Management 2Health News:Renaissance Medical Management Company Selects Allscripts Electronic Health Record and Practice Management 3Health News:Renaissance Medical Management Company Selects Allscripts Electronic Health Record and Practice Management 4Health News:Renaissance Medical Management Company Selects Allscripts Electronic Health Record and Practice Management 5Health News:Renaissance Medical Management Company Selects Allscripts Electronic Health Record and Practice Management 6Health News:Renaissance Medical Management Company Selects Allscripts Electronic Health Record and Practice Management 7Health News:Happy New Year for Marty: Arizona Man Drops 164 Pounds on Dr. Siegal's COOKIE DIET and Appears on ABC's Good Morning America 2Health News:Happy New Year for Marty: Arizona Man Drops 164 Pounds on Dr. Siegal's COOKIE DIET and Appears on ABC's Good Morning America 3Health News:New 20 Year Research Confirms the Biblical Assertion that Hebrew is the Original Proto-Language Confounded By the Gods 2Health News:New 20 Year Research Confirms the Biblical Assertion that Hebrew is the Original Proto-Language Confounded By the Gods 3Health News:New 20 Year Research Confirms the Biblical Assertion that Hebrew is the Original Proto-Language Confounded By the Gods 4Health News:Allscripts Reports Fiscal 2010 Second Quarter Results 2Health News:Allscripts Reports Fiscal 2010 Second Quarter Results 3Health News:Allscripts Reports Fiscal 2010 Second Quarter Results 4Health News:Allscripts Reports Fiscal 2010 Second Quarter Results 5Health News:Allscripts Reports Fiscal 2010 Second Quarter Results 6Health News:Allscripts Reports Fiscal 2010 Second Quarter Results 7Health News:Allscripts Reports Fiscal 2010 Second Quarter Results 8Health News:Allscripts Reports Fiscal 2010 Second Quarter Results 9Health News:Allscripts Reports Fiscal 2010 Second Quarter Results 10Health News:Allscripts Reports Fiscal 2010 Second Quarter Results 11Health News:Allscripts Reports Fiscal 2010 Second Quarter Results 12Health News:Allscripts Reports Fiscal 2010 Second Quarter Results 13Health News:Allscripts Reports Fiscal 2010 Second Quarter Results 14Health News:Allscripts Reports Fiscal 2010 Second Quarter Results 15Health News:Allscripts Reports Fiscal 2010 Second Quarter Results 16Health News:Allscripts Reports Fiscal 2010 Second Quarter Results 17Health News:Allscripts Reports Fiscal 2010 Second Quarter Results 18
... flexible care settings., ,IntelliVue MP40 ... and measurement flexibility to match the ... care environmentsat the patients side., ... patient monitoring, IntelliVue has highly flexible ...
... Built on Philips strong heritage in patient ... an extensive clinical measurements menu; built-in clinical ... derived 12-lead ECG, and arrhythmia analysis; and ... easy to use and operates on a ...
... to match the pace and unique needs ... on Philips strong heritage in patient monitoring, ... has highly flexible screen configuration; an extensive ... such as Event Surveillance, EASI derived 12-lead ...
... expands hospital-grade monitoring capabilities into the growing ... disease state management. The system is ... full range of clinical applications, from continuous ... to periodic monitoring of patients outside the ...
Medicine Products: